This was seen specifically for cases (between 9% and 11%) when apoA‐IV was added to the extended risk model 2 (including age, sex, eGFR, UACR, serum albumin, LDL cholesterol, smoking status, diabetes mellitus, statin use, triglycerides, BMI, systolic and diastolic blood pressure and CVD at baseline) concerning all four major endpoints: the NRI for cases for all‐cause mortality was 0.09 (95% CI: 0.04–0.16), for 3‐point MACE 0.07 (−0.001–0.17), 4‐point MACE 0.08 (0.02–0.15) and death and hospitalisations due to heart failure 0.11 (0.02–0.19). This evidence concerns the gene APOA4 and diabetes mellitus.